Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172177 | 0.78 | OR51E2 (0.39) | ALPLPOLBALPGALOX15TSHR | |
| SCHEMBL3675850 | 0.76 | ALOX15 (0.33) | ALPLPOLBALPGALOX15 | |
| SCHEMBL19628872 | 0.71 | — | — | |
| SCHEMBL27561660 | 0.69 | ALOX15 (0.31) | ALOX15TSHR | |
| SCHEMBL22479145 | 0.63 | GABRR1 (0.36) | ALPLPOLBALPGTSHRCHRM1 | |
| SCHEMBL6743070 | 0.63 | OR51E2 (0.36) | TSHRCHRM1 | |
| SCHEMBL3042219 | 0.63 | — | — | |
| SCHEMBL9405813 | 0.63 | — | — | |
| SCHEMBL13113139 | 0.61 | — | — | |
| SCHEMBL22231199 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200375929-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CANCER, INFLAMMATION, OR IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-03 | — | — | US | disclosed |
| EP-3668497-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CANCER, INFLAMMATION, OR IMMUNE RESPONSE | Washington University (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-2877486-B1 | PEPTIDE-BASED COMPOUNDS AND USES THEREOF TO TREAT BETA-AMYLOID ACCUMULATION | MANUS PHARMACEUTICALS CANADA LTD (CA) | 2019-05-01 | — | — | EP | disclosed |
| WO-2019036509-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CANCER, INFLAMMATION, OR IMMUNE RESPONSE | WASHINGTON UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-3418270-A1 | NOVEL BIPHENYLSULFOXIMINES AS ALLOSTERIC MODULATORS OF THE DOPAMINE D1 RECEPTOR | Universidad Complutense De Madrid (ES) | 2018-12-26 | — | — | EP | disclosed |
| US-20170266222-A1 | MODULATION OF CHRFAM7A FOR ANTI-INFLAMMATORY THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-21 | — | — | US | disclosed |
| US-9718869-B2 | Peptide-based compounds and uses thereof to treat beta-amyloid accumulation | MANUS PHARMACEUTICALS (CANADA) LTD. (CA) | 2017-08-01 | — | — | US | disclosed |
| EP-3193835-A1 | LIQUID INHALATION FORMULATION COMPRISING RPL554 | Verona Pharma PLC (GB) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016042313-A1 | LIQUID INHALATION FORMULATION COMPRISING RPL554 | VERONA PHARMA PLC (GB) | 2016-03-24 | — | — | WO | disclosed |
| US-20150337026-A1 | PEPTIDE-BASED COMPOUNDS AND USES THEREOF TO TREAT BETA-AMYLOID ACCUMULATION | PHARMA BIO LLC (RU) | 2015-11-26 | — | — | US | disclosed |
| US-8715676-B2 | Production and uses of type I ribosome inactivating proteins | BIOO SCIENTIFIC CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2598873-A2 | BIOMARKERS FOR PROSTATE CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2473199-A1 | ISOTOPICALLY LABELED NEUROCHEMICAL AGENTS AND USES THEREOF FOR DIAGNOSING CONDITIONS AND DISORDERS | Brain Watch Ltd. (IL) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012015904-A2 | BIOMARKERS FOR PROSTATE CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20110236366-A1 | PRODUCTION AND USES OF TYPE I RIBOSOME INACTIVATING PROTEINS | BIOO SCIENTIFIC CORPORATION | 2011-09-29 | — | — | US | disclosed |
| WO-2011024156-A1 | ISOTOPICALLY LABELED NEUROCHEMICAL AGENTS AND USES THEREOF FOR DIAGNOSING CONDITIONS AND DISORDERS | BRAIN WATCH LTD. (IL) | 2011-03-03 | — | — | WO | disclosed |
| WO-2005086590-A2 | MUSCLE-RELAXING PROTEINS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-09-22 | — | — | WO | disclosed |
| CN-1030480-A | The preparation technology of liquid ion-exchanger composite used as acetylcholine ion-selective microelectrode | UNIV ZHEJIANG (CN) | 1989-01-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375929-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CANCER, INFLAMMATION, OR IMMUNE RESPONSE | IKBKG, IKBKB, NFKBIA | ALPL 828/4885POLB 150/4885ALPG 1277/4885 |
| US-20150337026-A1 | PEPTIDE-BASED COMPOUNDS AND USES THEREOF TO TREAT BETA-AMYLOID ACCUMULATION | APP, IAPP, TTR | ALPL 1378/4885POLB 2129/4885ALPG 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.